You are here: Industry Insights > Pneumonia

News List

XENLETA Demonstrates High Efficacy in Community-Acquired Bacterial Pneumonia americanpharmaceuticalreview
October 16, 2020
Nabriva Therapeutics announced in a post-hoc analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 trials by age, XENLETA? (lefamulin) demonstrated consistently high efficacy and similar safety and tolerability profiles across all ...
RedHill Biopharma Announces Positive Recommendation from COVID-19 Study americanpharmaceuticalreview
August 31, 2020
RedHill Biopharma announced its U.S. Phase 2 study with opaganib (Yeliva?, ABC294640) in patients hospitalized with severe COVID-19 pneumonia, has successfully passed the first scheduled independent Safety Monitoring Committee (SMC) review.
Tradipitant may accelerate recovery from COVID-19 pneumonia, finds interim analysis europeanpharmaceuticalreview
August 20, 2020
A preliminary analysis of data from the first COVID-19 pneumonia patients enrolled in the ODYSSEY trial revealed that tradipitant may expedite clinical improvement.
Blade Therapeutics updates enrolment progress for Covid-19 pneumonia study of BLD-2660 pharmaceutical-business-review
August 18, 2020
Blade Therapeutics announced that the Phase 2 clinical study of the company’s investigational therapeutic, BLD-2660, has enrolled half of the anticipated 120 coronavirus disease-19 (COVID-19) pneumonia patients.
BioAegis Therapeutics Initiates Trial of Its Inflammation Regulator for COVID-19 Treatment americanpharmaceuticalreview
August 07, 2020
BioAegis Therapeutics enrolled its first patient in its Phase 2 study of hospitalized patients with severe COVID-19 pneumonia.
Nabriva Receives EC Approval for XENLETA for Community-Acquired Pneumonia americanpharmaceuticalreview
August 05, 2020
Nabriva Therapeutics announced the European Commission (EC) has issued a legally binding decision for approval of the marketing authorization application for XENLETA? (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults ...
Enzychem Files IND for Phase 2 Study of EC-18 in Preventing ARDS Due to COVID-19 Pneumonia americanpharmaceuticalreview
July 22, 2020
Enzychem Lifesciences has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a Phase 2 clinical trial of EC-18 as a preventative therapeutic against Acute Respiratory Disease Syndrome (ARDS) due to ...
BioAegis Therapeutics receives approval to proceed with phase 2 trial of its gelsolin Covid-19 treatment pharmaceutical-business-review
July 21, 2020
BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for its Phase 2 Proof of Concept study of its lead product, recombinant human plasma gelsolin (rhu-pGSN) in ...
Gilead announces results from Phase 3 Trial of remdesivir in patients with moderate COVID-19 worldpharmanews
June 17, 2020
Gilead Sciences, Inc. announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia.
PolyU collaborates with Macau, S.A.R., China University of Science and Technology to advance diagnosis of COVID-19 pneumonia prnewswire
June 16, 2020
COVID-19 is taking its toll on the world, affecting more than 200 countries and regions. In the face of a surge in cases, rapid diagnosis and identification of high-risk patients for early intervention is crucial for controlling the pandemic.